Error loading player: No playable sources found

M103a

Intensifying the Viral Vector Manufacturing Process: Challenges and Progress

Date
May 11, 2020
This product is not available for individual purchase, but it is available as part of the following products:
Thumbnail for CMC Strategy Forum Europe 2020
The purpose of the CMC Strategy Forum Europe 2020 is to offer a blend of topics that characterize the challenges facing the biotechnology industry in the next decade…

With several recent FDA approvals and a strong drug pipeline, gene therapy is coming of age. With this comes the requirement to ensure that there are robust manufacturing processes in place in order to scale with demand and to make these therapies readily accessible to those who need them. However, current manufacturing processes for gene therapies have often been developed with limited scalability in mind and large shifts in technology have to take place to enable industrialization. This also has to be done while keeping costs in mind. Here, we will present the challenges and solutions to scale up process steps required to develop manufacture iCELLis bioreactor process for scalable production, purification and analytics of AAV viral vector. After implementation of a large-scale of the entire process, we offer the client scalability and speed to the market

Speaker

Speaker Image for Rachel Legmann
Pall Life Sciences